Dr. Rajasree P. Chowdry, MD | New ...

Dr. Rajasree P. Chowdry

Claim this profile

University Medical Center New Orleans

Studies Skin Cancer
Studies Renal Cell Carcinoma
5 reported clinical trials
16 drugs studied

Area of expertise

1Skin Cancer
Rajasree P. Chowdry has run 4 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
CD4 count positive
CD4 count negative
2Renal Cell Carcinoma
Rajasree P. Chowdry has run 2 trials for Renal Cell Carcinoma. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
University Medical Center New Orleans
Image of trial facility.
East Jefferson General Hospital

Clinical Trials Rajasree P. Chowdry is currently running

Image of trial facility.

Cabozantinib +/− Atezolizumab

for Advanced Kidney Cancer

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Recruiting0 awards Phase 2

More about Rajasree P. Chowdry

Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Rajasree P. Chowdry has experience with
  • Nivolumab
  • Carboplatin
  • Paclitaxel
  • Cabozantinib
  • Ipilimumab
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Rajasree P. Chowdry specialize in?
Is Rajasree P. Chowdry currently recruiting for clinical trials?
Are there any treatments that Rajasree P. Chowdry has studied deeply?
What is the best way to schedule an appointment with Rajasree P. Chowdry?
What is the office address of Rajasree P. Chowdry?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security